Conference
Design of the AFFINITY study: A randomized phase III study of a novel clusterin inhibitor, custirsen, plus cabazitaxel/prednisone (CbzP) versus CbzP alone as second-line chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).
Authors
Beer TM; Biumenstein BA; Fizazi K; Hotte SJ; Jacobs C; Stewart PS
Volume
31
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Publication Date
May 20, 2013
Name of conference
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Conference place
Chicago, IL
Conference start date
May 31, 2013
Conference end date
June 4, 2013
Conference proceedings
JOURNAL OF CLINICAL ONCOLOGY
Issue
15
ISSN
0732-183X